Holen Sie sich die Stockscreener-App
17.57
2.39%
-0.445
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BAX?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$18.01
Offen:
$18.4
24-Stunden-Volumen:
2.20M
Relative Volume:
0.23
Marktkapitalisierung:
$9.04B
Einnahmen:
$11.24B
Nettoeinkommen (Verlust:
$-900.00M
KGV:
-10.46
EPS:
-1.679
Netto-Cashflow:
$323.00M
1W Leistung:
-0.63%
1M Leistung:
-11.17%
6M Leistung:
-26.72%
1J Leistung:
-49.12%
1-Tages-Spanne:
$17.51
$18.55
1-Wochen-Bereich:
$17.00
$18.55
52-Wochen-Spanne:
$17.00
$35.03
Baxter International Inc Stock (BAX) Company Profile
Firmenname
Baxter International Inc
Sektor
Telefon
(224) 948-2000
Adresse
ONE BAXTER PARKWAY, DEERFIELD, IL
Compare BAX vs ISRG, BDX, ALC, RMD, MDLN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
17.57 | 9.27B | 11.24B | -900.00M | 323.00M | -1.679 |
|
ISRG
Intuitive Surgical Inc
|
472.18 | 170.20B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
160.62 | 45.41B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
77.08 | 38.26B | 10.40B | 980.00M | 1.61B | 1.9749 |
|
RMD
Resmed Inc
|
231.80 | 33.86B | 5.40B | 1.49B | 1.78B | 10.12 |
|
MDLN
Medline Inc
|
40.92 | 33.33B | 28.43B | 1.16B | 1.26B | 1.4457 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-31 | Herabstufung | Argus | Buy → Hold |
| 2025-08-04 | Herabstufung | Stifel | Buy → Hold |
| 2025-08-01 | Herabstufung | Goldman | Buy → Neutral |
| 2025-02-26 | Fortgesetzt | Goldman | Buy |
| 2025-02-24 | Hochstufung | Argus | Hold → Buy |
| 2025-02-20 | Fortgesetzt | Barclays | Overweight |
| 2024-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-12-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-12-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-06-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-18 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2022-02-18 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-18 | Bestätigt | Raymond James | Outperform |
| 2022-02-18 | Bestätigt | Stifel | Buy |
| 2022-02-18 | Bestätigt | UBS | Neutral |
| 2022-02-18 | Bestätigt | Wells Fargo | Overweight |
| 2022-02-11 | Eingeleitet | Goldman | Neutral |
| 2022-01-07 | Fortgesetzt | Citigroup | Buy |
| 2022-01-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-09-13 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-09-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-06 | Herabstufung | UBS | Buy → Neutral |
| 2020-12-15 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-09-04 | Herabstufung | Argus | Buy → Hold |
| 2020-06-24 | Eingeleitet | Oppenheimer | Outperform |
| 2020-03-19 | Hochstufung | Stifel | Hold → Buy |
| 2020-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-26 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-04-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-01-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-01-02 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2018-11-02 | Hochstufung | Argus | Hold → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-05-17 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-06 | Bestätigt | Citigroup | Neutral |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
Alle ansehen
Baxter International Inc Aktie (BAX) Neueste Nachrichten
Intravenous (IV) Solutions Market Size to Reach USD 29.47 Billion by 2035 Due to the Increasing Prevalence of Chronic Diseases Globally | SNS Insider - GlobeNewswire Inc.
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Why Baxter International Inc. stock remains undervaluedJuly 2025 Reactions & Community Driven Trade Alerts - mfd.ru
Citigroup Lowers Price Target for Baxter International (BAX) Ami - GuruFocus
Baxter International (NYSE:BAX) Given New $19.00 Price Target at Citigroup - MarketBeat
Russell Investments Group Ltd. Has $57.24 Million Stock Position in Baxter International Inc. $BAX - MarketBeat
Baxter International Sees Unusually High Options Volume (NYSE:BAX) - MarketBeat
Baxter International (NYSE:BAX) Sets New 52-Week LowWhat's Next? - MarketBeat
Baxter International stock hits 52-week low at $17.26 - Investing.com India
Blood Tubing Set Market Is Going to Boom Rapidly | Baxter International • Terumo Corporation • Fresenius Kabi - openPR.com
Baxter International Inc. $BAX Stake Increased by Gamco Investors INC. ET AL - MarketBeat
Gabelli Funds LLC Has $15.87 Million Stock Position in Baxter International Inc. $BAX - MarketBeat
Is Baxter International Inc. stock a contrarian buyPortfolio Profit Report & Daily Chart Pattern Signals - Naître et grandir
Is Baxter International (BAX) Pricing In Too Much Bad News After Its Sharp Share Price Fall - simplywall.st
Baxter Reshapes Portfolio With Kidney Spin Off And Margin Focus - Yahoo Finance
How Baxter International Inc. stock valuations compare to rivalsOil Prices & Weekly Setup with ROI Potential - Naître et grandir
Will Baxter International Inc. stock recover faster than peersTrade Volume Summary & Real-Time Volume Triggers - Naître et grandir
Why Baxter International Inc. stock could be next big winnerExit Point & AI Forecasted Entry and Exit Points - Naître et grandir
Baxter International Inc (BAX) Shares Gap Down to $17.875 on Mar 6 - GuruFocus
Sticking With Baxter At The Lows (NYSE:BAX) - Seeking Alpha
Reassessing Baxter International (BAX) Valuation After Recent Share Price Weakness - Sahm
Q1 EPS Estimate for Baxter International Lowered by Analyst - MarketBeat
Baxter Joins the National Infusion Collaborative to Advance Infusion Safety and Best Practices - The National Law Review
Global Hollow Fiber Dialyzer Market Size, Growth, Trends & - openPR.com
Baxter International: Spin-Off Nears As Wall Street Re-Rates The Stock - AD HOC NEWS
Baxter International Inc. (NYSE:BAX) Short Interest Update - MarketBeat
Baxter International (NYSE:BAX) Upgraded at Zacks Research - MarketBeat
Baxter International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Baxter International Inc. stock underperforms Monday when compared to competitors - MarketWatch
Q4 Earnings Highs And Lows: Baxter (NYSE:BAX) Vs The Rest Of The Medical Devices & SuppliesDiversified Stocks - Yahoo! Finance Canada
Baxter International Inc (BAX) Trading Down 4.86% on Mar 2 - GuruFocus
Baxter International Inc. (BAX) Stock Analysis: Navigating Opportunities with a 6.20% Potential Upside - DirectorsTalk Interviews
DNB Asset Management AS Raises Stock Holdings in Baxter International Inc. $BAX - MarketBeat
Analysts Offer Insights on Healthcare Companies: Baxter International (BAX), Nautilus Biotechnolgy (NAUT) and Delcath Systems (DCTH) - The Globe and Mail
BAX SEC FilingsBaxter Intl Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Robert Davis, 39 - Crain's Chicago Business
Understanding Baxter International's Role in MedTech - www.whatjobs.com
Baxter International Inc.: - marketscreener.com
Baxter International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Baxter at Citi’s MedTech Day: Strategic Shifts Amidst Challenges - Investing.com
Baxter International Inc To Go Ex-Dividend On February 27th, 2026 With 0.01 USD Dividend Per Share - 富途牛牛
Siemens, Baxter, Hilton & more dividends 2026 • Vienna Stock Exchange - Wiener Börse
Ex-Dividend Reminder: MGE Energy, Labcorp Holdings and Baxter International - Nasdaq
Argus Research Maintains Baxter International Inc(BAX.US) With Hold Rating - 富途牛牛
Infusion Stand Market Is Going to Boom | BD • Baxter International • Smiths Medical - openPR.com
Baxter Investors Face a Test of Patience Amid Corporate Overhaul - AD HOC NEWS
Is Baxter International (BAX) Pricing In Its Turnaround After Years Of Share Price Weakness? - simplywall.st
Baxter International's $3 Billion Sales Base Facing Earnings Pressure - Smartkarma
Baxter is one of the S&P 500’s worst performers today. Earnings were brutal. - MSN
Baxter’s Ongoing Losses And Impairments Test The Investment Narrative - Yahoo Finance
Baxter International Inc. (BAX) Stock Analysis: Navigating Through Challenges with Strategic Resilience - DirectorsTalk Interviews
Finanzdaten der Baxter International Inc-Aktie (BAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.00%
0.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):